Navigation Links
Robert G. Savage, Former Worldwide Chairman, Johnson & Johnson's Pharmaceuticals Group, Joins Board of Nuovo Biologics, LLC
Date:9/10/2012

MIAMI, Sept. 10, 2012 /PRNewswire/ -- Nuovo Biologics, LLC announced that Robert G. Savage has joined its Board. Mr. Savage served as Group Vice President and President – General Therapeutics & Inflammation Business of Pharmacia Corporation from 2002 until its acquisition by Pfizer, Inc. in 2003.  From 1996 through 2001, Mr. Savage served Johnson & Johnson in a variety of roles, most recently as Worldwide Chairman of Johnson and Johnson's Pharmaceutical Group.  From 1985 to 1996 he served Roche Holding AG in a variety of senior marketing, business development and operations positions, most recently as Vice President – Marketing, Hoffman-La Roche, Inc.  He is currently a director of EpiCept Corporation and The Medicines Company.  Mr. Savage was a member of the Board of Directors of Noven Pharmaceuticals, Inc. from 2004 until 2009 when the company was sold to Hisamitsu Pharmaceuticals Company.  Mr. Savage has been the President of Strategic Imagery LLC, a pharmaceutical consultancy, since 2003. 

Donald A. Denkhaus, Chairman of the Board of Nuovo Biologics stated, "We are exceptionally fortunate to have a pharmaceutical executive with such a wealth of experience join our Board.  Bob's leadership, strategic vision and marketing experience will help move our company to the next level." 

Dr. Jay Yourist, CEO said, "Nuovo's first drug in the U.S. will be a broad spectrum antiviral to treat companion animals. Ultimately, approval for human uses for our drugs will be sought. We are particularly pleased that Bob is joining our Board, especially in light of his past responsibility of developing and launching several antiviral and anti-bacterial drugs including Rocephin (ceftriaxone) and Tamiflu (oseltamivir) while he was at Roche and Levaquin (levofloxacin) while he was at Johnson & Johnson."  Tamiflu is currently a leading antiviral drug with billions in sales globally since its launch.

Nuovo Biologics, LLC is a Florida based biopharmaceutical company that is pursing innovative health products and technologies.


'/>"/>
SOURCE Nuovo Biologics, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lilly Announces Retirement of Robert Armitage, Names Michael Harrington Senior Vice President and General Counsel
2. PAREXEL International to Present at Robert Baird Healthcare Conference
3. Lance Armstrong Update: Arrogant Even After Conceding Doping Charges, Asserts Former White House & WADA Spokesman Robert Weiner; Victory for Clean Sport but "Dark Message" Is Science Must Catch Up to Masking Agents Allowing Cheating
4. ARAMARK Healthcare Technologies Taps Robert Steele to Lead ReMedPar
5. ReShape Medical Appoints Robert E. Grant to Board of Directors
6. Cell Therapeutics, Inc. (CTI) Appoints Former Managing Director, Head of West Coast Biotechnology for Oppenheimer/CIBC Matthew J. Plunkett Executive Vice President, Corporate Development
7. Mike Golic, ESPN Radio Personality and Former Philadelphia Eagle, Holds Pre-Season "Training Camp" for People With Type 2 Diabetes
8. Par Formulations (Formerly Edict Pharmaceuticals) Receives First ANDA Approval
9. Phonak and Special Olympics join forces with US Olympian, former Congressman Jim Ryun
10. Judge Upholds $3.3 Million Judgment In Favor of Fox Insurance Company Against Former Pharmacy Benefit Manager
11. Former NxStage Patient Nikolas Gieske Celebrates Kidney Transplant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host its fiscal ... Friday, November 3, 2017, beginning at 7:00 a.m. (CDT) ... a.m. (CDT) / 9:30 a.m. (EDT). In ... guidance for 2018, Hill-Rom executives will also highlight the ... long-range financial outlook through 2020. ...
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... As health professionals work to improve their approach to healthcare, there is ... than filling out a survey; in many cases health professionals and patients are working ... and research on the importance of active engagement with patients and members of the ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The American ... to become its next President and Chief Executive Officer, succeeding Dr. James C. Puffer ... Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health and Nutrition ... the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD market ... can be easily incorporated into liquid products, while reducing costs to end users. , ...
(Date:10/13/2017)... ... ... Lori R. Somekh, founder of the Law Office of Somekh & Associates ... special needs planning attorneys. “Membership in ElderCounsel helps our office remain up to date ... elder law attorneys nationwide,” said Somekh. , ElderCounsel was founded by ...
(Date:10/13/2017)... Calif. (PRWEB) , ... October 13, 2017 , ... Many ... dementia. However, many long-term care insurance companies have a waiver for care if the ... 90-day elimination period, when the family pays for care, is often waived, so the ...
Breaking Medicine News(10 mins):